What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.
Athersys Completes Enrollment in Ulcerative Colitis Trial; Results Pending
Dec 19, 2013
(ATHX) and partner Pfizer announced
completion of patient enrollment in their Phase 2 trial of MultiStem cells for ulcerative colitis. The trial
, initiated in 2010, has weathered numerous recruitment-associated delays, but now looks to report its eagerly awaited results "in the second quarter of 2014."
New Life For Athersys' Stroke Trial
Aug 27, 2013
After languishing for nearly two years with just a single recruiting site and no record updates, Athersys
' (ATHX) Phase 2 stroke trial showed new life in its most recent update
, introducing 32 new sites, 22 of which are actively recruiting, thereby prompting our Clinical Trials Monitor
to upgrade the trial from red- to yellow-flag status.
Athersys Acknowledges Recruiting Challenge, Sees Colitis Trial Results in Early 2014
Aug 15, 2013
Acknowledging a slow recruitment pace for Athersys
(ATHX) partner Pfizer's trial of MultiStem cells in ulcerative colitis due to competition for patients among numerous trials, CEO Van Bokkelen noted
a trend our Clinical Trials Monitor
first flagged in May of this year. Pfizer and Athersys expect results "early in 2014."
Athersys Confirms Plans to Launch Phase 2 Heart Attack Trial
Aug 13, 2013
On the heels of a promising Phase 1 trial and a new $2.8 million grant, Athersys
it will launch a Phase 2 heart attack clinical trial for MultiStem "early next year."
Athersys Wins $2.8M Grant To Support Phase 2 Cardiac Trial
Aug 6, 2013
receipt of a $2.8M SBIR grant from the U.S. National Heart, Lung, and Blood Institute to support a Phase 2 trial of MultiStem cells in heart attack.
Athersys (ATHX) continues climb
Apr 16, 2013
From their late-March low, Athersys
) shares have risen almost 50%, perhaps in anticipation of good news from its promised
"second half of 2013" initial results of ulcerative colitis trial with Pfizer. Institutional buying has been strong.
Athersys (ATHX) up on preclinical publications
Apr 10, 2013
) shares were up nearly 10% at mid-day on publication
of preclinical data on MultiStems' potential in allograft rejection (with Pfizer) and peripheral vascular disease (with OHSU).
Short interest in Athersys (ATHX) shares up in March
Mar 28, 2013
) is the only SCSI component this week to make Bloomberg's list
of top short-interest increases in March. ATHX shorts were up 14%.
Athersys (ATHX) tops the SCSI
Mar 14, 2013
Athersys< Previous Page
) became the best performing SCSI stock for the year-to-date, up 34.8% since January 1st.
| Next Page >